Acceleron Pharma Inc. Daily Stock Analysis

Daily Stock Analysis, XLRN, Acceleron Pharma Inc, priceseries

Acceleron Pharma Inc. Daily Stock Analysis
Stock Information
Open
179.85
Close
178.75
High
179.85
Low
177.06
Previous Close
179.68
Daily Price Gain
-0.93
YTD High
189.99
YTD High Date
Sep 29, 2021
YTD Low
111.75
YTD Low Date
May 11, 2021
YTD Price Change
54.44
YTD Gain
43.79%
52 Week High
189.99
52 Week High Date
Sep 29, 2021
52 Week Low
111.75
52 Week Low Date
May 11, 2021
52 Week Price Change
54.47
52 Week Gain
43.83%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 24. 2017
29.13
May 8. 2017
30.94
10 Trading Days
6.20%
Link
LONG
Jun 16. 2017
29.69
Jun 26. 2017
31.49
6 Trading Days
6.08%
Link
LONG
Aug 23. 2017
34.29
Sep 20. 2017
38.15
19 Trading Days
11.25%
Link
LONG
Dec 20. 2017
38.24
Jan 5. 2018
42.20
10 Trading Days
10.37%
Link
LONG
Nov 22. 2019
44.37
Dec 6. 2019
47.05
9 Trading Days
6.03%
Link
LONG
Jan 28. 2020
79.39
Feb 24. 2020
91.78
18 Trading Days
15.60%
Link
LONG
Feb 3. 2021
120.97
Feb 16. 2021
127.66
8 Trading Days
5.53%
Link
LONG
Sep 17. 2021
137.60
Oct 13. 2021
173.17
18 Trading Days
25.85%
Link
Company Information
Stock Symbol
XLRN
Exchange
NasdaqGM
Company URL
http://www.acceleronpharma.com
Company Phone
617-649-9200
CEO
Habib J. Dable
Headquarters
Massachusetts
Business Address
128 SIDNEY STREET, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001280600
About

Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Description

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The company's therapeutic candidates also include Dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading